ONCO · Onconetix, Inc.

On April 30, 2026, Onconetix, Inc. held a special meeting of stockholders to vote on two primary proposals. The first and most significant proposal authorized the Board of Directors to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock. The approved split ratio falls within a range of 1-for-2 to 1-for-10, with the exact ratio to be determined by the Board without further stockholder approval. This authorization is valid until the one-year anniversary of the special meeting. The proposal received substantial support, with approximately 1.30 million votes cast in favor versus approximately 0.25 million against. The second proposal, regarding the potential adjournment of the meeting to solicit additional proxies if necessary, was also approved by stockholders. The votes were based on an aggregate of 3,464,686 shares of common stock outstanding as of the record date of March 13, 2016. Both matters were approved, allowing the company to proceed with the reverse stock split at the Board's discretion within the specified timeframe.